Journal issues > Issue 5, September 2017 > Highlights in lymphoproliferative disorders from the French Society of Hematology congress (Paris, 15-17 March 2017)

Highlights in lymphoproliferative disorders from the French Society of Hematology congress (Paris, 15-17 March 2017)

By: A. Bosly MD, PhD

SUMMARY

Some highlights of the 2017 French Society of Hematology meeting are summarised. The T-cell lymphoma most frequent, angioimmunoblastic lymphoma is now recognised as derived from follicular helper T-cells. No major advancement in the treatment of T-cell lymphoma has been obtained. However many new drugs are promising, especially Brentuximab Vedotin for CD30 lymphoma. Two publications were presented as favourites (coup de cœur): phase III in primary CNS lymphoma and long term results of CLL8 trial. Two major publications from the LYSA group were reported: the Lyma trial in MCL demonstrated efficacy of rituximab maintenance and the Remarc trial showed efficacy of lenalidomide after R-CHOP in DLBCL to prolong DFS.

(BELG J HEMATOL 2017;8(5):201–2)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €2.42

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top